Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $24.92, up 1.18% on the session, giving a market capitalisation of $4.06B. On trailing twelve-month figures it carries a trailing P/E of -29.32, a net margin of -229.9%. Its beta of 1.12 implies it has historically moved more than the broad market.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Tango Therapeutics, Inc. is most often compared with the following Healthcare names: